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Abstract
A murine monoclonal antibody, m357, showing the highly neutralizing activities for human tumor necrosis factor (TNF-a)
was chosen to be humanized by a variable domain resurfacing approach. The non-conserved surface residues in the
framework regions of both the heavy and light chain variable regions were identified via a molecular modeling of m357
built by computer-assisted homology modeling. By replacing these critical surface residues with the human counterparts, a
humanized version, h357, was generated. The humanized h357 IgG1 was then stably expressed in a mammalian cell line and
the purified antibody maintained the high antigen binding affinity as compared with the parental m357 based on a soluble
TNF-a neutralization bioassay. Furthermore, h357 IgG1 possesses the ability to mediate antibody-dependent cell-mediated
cytotoxicity and complement dependent cytotoxicity upon binding to cells bearing the transmembrane form of TNF-a.I na
mouse model of collagen antibody-induced arthritis, h357 IgG significantly inhibited disease progression by intra-peritoneal
injection of 50 mg/mouse once-daily for 9 consecutive days. These results provided a basis for the development of h357 IgG
as therapeutic use.
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Introduction
Tumor necrosis factor (TNF-a) is a pro-inflammatory cytokine
produced primarily by cells of the immune system, including
macrophages and monocytes. TNF-a is present as a homotrimeric
protein in which each subunit is initially translated as a 26 kDa
transmembrane precursor protein. After being cleaved at a site
proximal to the transmembrane domain of TNF-a by TNF-a
converting enzyme, a soluble trimeric form of TNF-a is released
and exerts its activity by binding to two structurally distinct type I
and type II TNF receptors (TNFRI and TNFRII) on effector cells.
The transmembrane form of TNF-a is also known as its unique
biologic functions, such as cytotoxic activity and polyclonal B cell
activation, in a cell-to-cell contact manner [1]. TNF-a has been
proved to have certain effects on autoimmune processes and has
become a key therapeutic target for many autoimmune diseases
[2]. So far, some anti-TNF-a agents, like etanercept, adalimumab
and infliximab were approved by the Food and Drug Adminis-
tration, and all have the capability to neutralize soluble form of
TNF-a effectively as a major pharmacological mechanism of
action. However, the binding effects of these antagonists on the
transmembrane form of TNF-a are different, which may cause
different results on clinical diseases [3]. For instance, etanercept is
not clinically effective for the pathogenesis of granulomatous
diseases, in which the transmembrane form of TNF-a may play a
critical role [1]. Therefore, whether or not anti-TNF-a agents can
bind to the transmembrane form of TNF-a is prerequisite to
trigger antibody dependent cell mediated cytotoxicity (ADCC),
complement dependent cytotoxicity (CDC), apoptotic and outside-
to-inside signaling mechanisms.
The major impediment of the murine monoclonal antibody in
clinical practice is that it may elicit human anti-murine antibody
(HAMA) response in patients [4,5,6]. Hence, to improve the
efficiency in clinical use, genetic engineering technology has been
employed to replace the murine content with the amino acid
residues of human counterparts, and to reduce the possibility of
inducing immunogenicity in patients. An ideal antibody human-
ization should be capable of maintaining the specificity and affinity
toward the antigen and reduces the immunogenicity as much as
possible. So far, many approaches have been used for antibody
humanization, such as chimeric antibodies, which consists of
murine antigen-binding variable regions fused genetically to
human antibody constant regions, is the earliest attempt to reduce
immunogenicity [7]. However, chimeric antibodies still generate
undesirable anti-variable region response [8]. Complementarity
determining region (CDR)-grafting is another approach involving
the transfer of the CDRs from a rodent antibody to the Fv
frameworks (FRs) of a human antibody [9]. Unfortunately, the
interface changes between CDRs and new FRs may largely disturb
the binding to the antigen. The initial CDR-grafted antibodies
tend to lose the parental binding affinity, and therefore require
additional work for back-mutation of several murine framework
amino acids, which are regarded to be crucial for CDRs loop
conformation [10]. Humanization via variable domain resurfacing
is another approach that can maintain the specificity and binding
affinity of parental antibody, which can reduce the immunoge-
nicity of antibodies through the replacement of surface exposed
residues in the murine FRs with those usually found in human
antibodies [11,12,13,14,15]. Although the current molecular-
biology techniques can render this approach more straightforward
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exposed in solvent on the surface, especially when requiring a
reliable computer model of the antibody [14].
This study is in an attempt to humanize a murine anti-human
TNF-a monoclonal antibody, m357, raised by immunization of
mice with recombinant human TNF-a. In order to keep the
parentalbindingaffinity,weresurfacedm357 inthevariableregions
of both the heavy and light chains via computer-aided molecular
modeling followed by functional characterization of the humanized
antibody. The results indicated that the humanized antibody, h357,
retained in vitro bioactivities similar to the parental antibody.
Moreover, the humanized h357 IgG is capable of binding to the
cells bearing the transmembraneTNF-a and triggering ADCC with
effector cells and CDC. The humanized 357 IgG at a dose level of
50 mg/mouse/day significantly inhibited disease progression in a
mouse model of collagen antibody-induced arthritis when com-
pared with saline treatedmice. These results provided a basis for the
development of h357 IgG as therapeutic use.
Results
Molecular modeling of m357 variable fragments
Themurinemonoclonalantibodyderivedfromthehybridomacell
line, 357-101-4 (ECACC No. 92030603), is of therapeutic interest for
its reported strong neutralizing biological activity against human
TNF-a [16] The cDNAs encoding the heavy chain variable region
(VH) and light chain variable region (VL)o ft h em u r i n ea n t i - h u m a n
TNF-amonoclonalantibody (designatedasm357)were firstobtained
by RT-PCR (Figure S1). The three-dimensional structure of the
deduced amino acid sequences of the VH and VL fragments of m357
was constructed individually by homology modeling (program
MODELLER) as described under ‘‘Materials and Methods’’.
Afterward, molecular models of the VH and VL domains of m357
were created using the crystal structures of the VHdomain of the anti-
breast tumour antibody SM3 (PDB code 1SM3; 87% sequence
identity) [17] and the VL domain of the anti-Thermus aquaticus
DNA polymerase I antibody (PDB code 1AY1; 85% sequence
identity) [18], respectively. The final refined structures of the VH and
VL domains of m357 were obtained through Discovery Studio
modeling 2.1 program as shown in Figure 1.
Humanization of m357 variable fragments
Humanization by variable domain resurfacing was first
proposed by Padlan in 1991, in which the potential antigenic
sites in the framework regions of an antibody were eliminated
without affecting the antigen binding affinity [11]. This method is
based on the hypothesis that the human anti-mouse antibody
(HAMA) response to the variable region derives from the surface
residues only and has adopted and modified by other researchers
[14,15,19]. In this study, we performed the variable domain
resurfacing of m357 with the following three steps: first, the
molecular models of the VH and VL domains of m357 were
constructed individually; second, we used AREAIMOL program
to calculate the solvent accessible residues for identifying the non-
human like framework surface residues, and finally we mutated
these surface residues to the human counterparts according the
results of the sequence alignment of human framework. In order to
replace the non-human like framework surface residues of the
murine m357 on the variable domain, a set of highly homologous
surface residues from a human target sequence were selected. We
searched the IMGT database (http://imgt.cines.fr/) to identify the
human VH and VL sequence pairs, which are most homologous to
the corresponding variable regions of m357, while eliminating the
sequences of phage-display or humanized antibodies from our
search results. The most identical surface residues found from
human sequences were the variable regions of PPS4 (VH: 76% and
VL: 73% in sequence identity in the FRs, respectively) (Genbank
DQ187629 and DQ187550) (Figure 2). According to the
calculation results of AREAIMOL program, 8 out of the 20
surface residues in the VH were non-conserved between human
and mouse sequences and 9 out of 16 surface residues were non-
conserved in the VL. These 17 surface residues were the
candidates to be replaced. However, the substitution of H52BQ,
H52CS, H54N, H61E, L31F, L55S, L90W, L92D, L93Y and
L96R in CDR regions may potentially alter the CDR’s
conformation, and V59, an additional non-conserved surface
residue in light chain near the CDR2 within 5 A ˚, may potentially
affect the binding affinity too. As a result, these 11 murine residues
were retained for preserving the antigen binding affinity. Finally,
the remaining 6 residues: H3KRQ, H11WRL, H19KRR,
H42ERG, L10IRT and L18KRR were chosen to be replaced
to the human conserved residues (Figure 1).
Construction and expression of the humanized 357 IgG1
The amino acid sequences of the humanized VH and VL of
m357, comprising the signal peptide at the N-terminus, were in-
frame fused to the human IgG c1 heavy chain and kappa light
chain constant regions, respectively. For the expression of an intact
humanized 357 (h357) IgG1 molecule, two different mammalian
expression vectors, pSecTag2/Hygro and pcDNA3.3, were used
to adopt the humanized heavy chain and light chain of h357 IgG,
respectively. After co-transfection and antibiotic selection, one of
the clones showing the highest expression level was chosen for
further studies. The expression level of the recombinant h357 IgG
was ,14 mg/L. Both m357 and h357 IgGs were purified by
protein A chromatography individually and the protein purities
were determined by SDS-PAGE. As shown in Figure 3, under
Figure 1. Molecular model of the m357 variable regions. The
three-dimensional structure of m357 was generated by homology
modeling using the crystal structures of the anti-breast tumor antibody
SM3 (PDB code 1SM3) and the anti-Thermus aquaticus DNA polymerase
I antibody (PDB code 1AY1) for the VH and VL domains, respectively. The
six residues which are preferably mutated to ‘‘human’’ amino acid are
indicated by stick structures (green). Four residues in the VH framework
and two residues in the VL framework were humanized. Valine 59,
which is within about 5 A ˚ of the CDR2 in light chain and may affect the
antigen binding, is retained for preserving the antigen binding affinity
and shown as stick structure (orange). The CDR loops are shown in red
color.
doi:10.1371/journal.pone.0016373.g001
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with a molecular mass of 155 kDa (lanes 1 and 3). Under reducing
conditions, both antibodies yielded two protein bands with
molecular masses of 55 kDa (heavy chain) and 26 kDa (light
chain) (lanes 2 and 4).
Neutralization of TNF-a-mediated cellular cytotoxicity by
m357 and h357
To examine the functional activity of the anti-TNF-a
antibodies, the ability of the antibody to inhibit soluble TNF-a
activity was performed. TNF-a causes cell cytotoxicity to murine
L929 cells. Both m357 and h357 IgGs were evaluated in L929
assays by co-incubation of antibodies with recombinant human
TNF-a. As shown in Figure 4, TNF-a-mediated cytotoxicity in
L929 cells treated with 100 ng/ml of human TNF-a was
effectively neutralized by both m357 and h357 IgGs in a dose
dependent manner, with ED50 of 3.07 nM and 2.30 nM,
respectively. The results indicated that the humanized 357 IgG
retained the TNF-a neutralization activity at concentrations
similar to that of the murine IgG.
Binding affinities of h357 IgG to soluble and membrane
form TNF-a
A higher binding affinity between antagonists and soluble TNF-
a can help maintain the stability of neutralizing complex and
become a critical factor for neutralizing activity of anti-TNF-a
antibodies [2]. The relative binding affinities of h357, m357 IgGs
and two marketed TNF-a antagonists, etanercept and adalimu-
mab, to soluble form TNF-a were compared by ELISA binding
assays. As shown in Figure 5A, the binding affinities of h357,
m357, etanercept and adalimumab for soluble human TNF-a
were all in the nanomolar range, with KD values of approximately
7.8 nM, 5.5 nM, 2.2 nM and 2.9 nM, respectively. The similar
KD values in h357 and m357 IgGs indicated that the
humanization process did not alter the TNF-a binding strength
of the parental mouse antibody.
TNF-a exists as a membrane associated precursor (transmem-
brane TNF-a) from which the mature soluble form is released by
proteolytic cleavage mediated by TNF-a converting enzyme.
Many studies have investigated that TNF-a antagonists can cause
cell lysis by apoptotic, ADCC, CDC and outside-to-inside
signaling mechanisms given that it has the binding ability to
transmembrane TNF-a [1,20,21,22]. To analyze the transmem-
brane TNF-a binding ability of h357, we transfected an
uncleavable form of transmembrane TNF-a cDNA into NS0 cells
to express it on the cell surface, and used flow cytometry to assess
the binding activities of both m357 and h357 IgGs. The data in
Figure 5B indicated that both m357 and h357 IgGs can bind to
transmembrane TNF-a in a concentration-dependent manner,
with KD of 12.0 nM and 16.8 nM, respectively. The similar KD
values in m357 and h357 indicated that the humanization process
did not alter the transmembrane TNF-a binding affinity. The
binding affinity in the nanomolar range suggested h357 IgG could
potentially trigger more effector functions or apoptosis mechanism
through binding to transmembrane TNF-a.
Ability of h357 and m357 to mediate ADCC and CDC
Previous studies have been reported that the binding affinity of
infliximab and adalimumab toward the membrane form of TNF-a
were better than that of etanercept, which can affect the cell killing of
cell surface-expressed TNF-a by ADCC, CDC or apoptosis
mechanisms and this may be one of reasons that cause different
effects on clinical diseases [3]. Cell surface-expressed TNF-a like
macrophages and monocytes play a critical role in the Granuloma-
tous diseases such as Crohn’s disease and Wegener’s granulomatosis,
and the cells can be killed directly by ADCC or CDC effects [23].
WhenTNF-aantagonists bind to cells expressing the transmembrane
form of TNF-a, these cells will be targeted by natural killer cells or
triggered the activation of systemic complement. The presence of the
Fc region of human IgG1 in h357 may potentially cause cell lysis in
TNF-a-producing cells through effector functions. The ability of
h357 and m357 IgGs to mediate ADCC and CDC against the cells
expressing the transmembrane form of TNF-a were conducted. In
Figure 2. Amino acid sequence alignment of the VH (A) and VL (B) domains of m357 and PPS4. The sequences of PPS4 Fv which were the
most homologous to m357 Fv used as the acceptor of human surface residues for m357 humanization is shown as PPS4VL and PPS4VH for
comparison. CDR residues were within brackets. Conserved surface residues were marked with clear boxes, and non-conserved surface residues were
marked with shadowed boxes. Amino acid sequences are numbered according to the Kabat’s convention[33].
doi:10.1371/journal.pone.0016373.g002
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were lysed by h357 IgG at 6.25 mg/ml at a 20:1 effector to target
(E:T) ratio (Figure 6A).In CDC assay, h357 IgG was also capablein
lysing transmembrane TNF-a cells in the presence of human
complement (Figure 6B). In contrast, m357 IgG exhibits neither
ADCC nor complement-mediated lysis because the human natural
killer cellsor systemic complement are unableto recognize the mouse
Fc fragment (Figure 6). These data indicated that h357 IgG can
mediate ADCC and CDC effects upon binding to the transmem-
brane TNF-a expressed on cell surface and therefore it possesses the
potential to be developed into a more effective TNF-a-neutralizing
antibody similar to those therapeutic antibodies with ADCC and
CDC capabilities.
In vivo inhibition of murine collagen antibody-induced
arthritis with h357 IgG
To assess the therapeutic effects of h357 on rheumatoid arthritis
development, the collagen antibody-induced arthritis mouse
model was adopted, in which the disease was induced by the
systemic administration of a cocktail of monoclonal antibodies that
target various regions of collagen type II, which is one of the major
constituents of articular cartilage matrix proteins, followed by
lipopolysaccharides [24]. The mice were intraperitoneally injected
with h357 IgG (50 mg/mouse) or phosphate buffered saline (non-
treatment group) once-daily for 9 consecutive days. As shown in
Figure 7, progressed to significantly less severe disease than the
saline-treated mice group (P,0.05).
Discussion
TNF-a antagonists, including antibodies, have been developed
for binding to TNF-a as a mean to inhibit its biological activities,
including TNF-a-induced cell activation and cytotoxicity. Anti-
TNF-a therapies have been applied to a variety of autoimmune
disorders, such as rheumatoid arthritis [25], inflammatory bowel
disease [26] and systemic lupus erythematosus [27]. A common
feature of these therapeutic antibodies is that they all have the
capacity to neutralize soluble form of TNF-a activity effectively
with high binding affinity in the range of nM or less. Meanwhile,
antibodies with slow dissociation kinetics and good pharmaco-
kinetics are also required since TNF-a is secreted constitutively
from the activated macrophages, monocytes, and lymphocytes
from patients with the above chronic inflammatory diseases. In
this study, we adopted a reported murine anti-human TNF-a
antibody with strong neutralizing activity against TNF-a [16] for
humanization by resurfacing approach. The humanized h357
IgG retained the high antigen binding affinity and bioactivity as
compared with the parental murine IgG based on TNF-a
binding and neutralization assays, respectively. We also com-
pared the relative TNF-a binding affinity of h357 IgG with two
anti-TNF-a agents, the monoclonal anti-TNF-a antibody
adalimumab and the soluble TNF receptor fusion etanercept.
Although the relative binding affinity of h357 IgG is slightly
lower than both etanercept and adalimumab, the relative TNF-a
neutralization activities were found to be similar (data not
shown). It is possible that the binding kinetics (association and
dissociation rates) among these anti-TNF-a agents are different.
Further studies in the binding kinetics of h357 IgG need to be
conducted to elucidate the correlation between binding affinity
and bioactivity. In the mean time, affinity maturation by CDR-
shuffling using phage display approaches may need to be
adopted if further affinity improvement of h357 IgG is required
for therapeutic use.
Protein therapeutics from exogenous sources can potentially
elicit immune response when administered in humans. The anti-
drug antibodies could lead to partially or completely loss of drug
efficacy. Preclinical immunogenicity assessment has drawn a lot
of attention to FDA and is highly encouraged in the preclinical
development stages. Many techniques, such as humanization,
deimmunization and deaggrgation have been adopted to alter
the structure of a protein in order to reduce the potential risk of
immugenecity. Antibody humanization by CDR-grafting can
often result in decrease or completely loss of antigen binding
affinity because the murine frame-work regions encompassing
Figure 3. Purification of m357 and h357 antibodies.T h e
indicated m357 (lanes 1 and 2) and h357 (lanes 3 and 4) were
expressed in the mouse myeloma NS0 cells and purified from culture
media by protein A column. The samples were electrophoresed on a
4,12% SDS/Bis-Tris polyacrylamide gel with MOPS buffer under non-
reducing conditions (lanes 1 and 3) and reducing conditions (lanes 2
and 4). Gel was stained with Coommassie blue. M, molecular mass
standards.
doi:10.1371/journal.pone.0016373.g003
Figure 4. Neutralization of TNF-a-mediated cytotoxicity in
L929 cells by m357 and h357 antibodies. Various concentrations
of m357 (N
) and h357 (#) antibodies were added to L929 cells cultured
with 100 ng/ml of recombinant human TNF-a. The cells were incubated
for 16 hrs at 37uC and cell viability was analyzed using a colorimetric
MTT assay.
doi:10.1371/journal.pone.0016373.g004
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structure for the formation of correct CDR-epitope complex.
T h ed e i m m u n i z a t i o na p p r o a c hw eh a v ea d o p t e di sat h r e e
dimensional structure resurfacing method based on the fact that
most antigenic response to the variable region is directed to
surface residues only. By replacing the amino acids that are
potentially antigenic whereas preserving the most murine
primary structure in the variable regions should in theory
minimize the conformational change of the parental murine
antibody and thus retain the antigen binding affinity. So far,
there is little information available about the effects of antibody
deimmunization by resurfacing on the antigen binding affinities.
Figure 5. Binding affinities of h357 IgG to soluble and membrane form TNF-a. (A) Binding affinities of different TNF-a anatagonists to
soluble TNF-a. Microtiter plates with the anti-human IgG Fcc fragment captured h357 (N
), etanercept (.) and adalimumab (g) and the anti-mouse
IgG Fcc fragment captured m357 (#) were incubated with various concentrations of soluble TNF-a for 1 hr at 37uC. After washing, the bound TNF-a
was detected by a mouse monoclonal anti-TNF-a antibody conjugated with horseradish peroxidase. Absorbance was read at 450 nm on a microplate
reader. (B) The saturation binding curves of m357 and h357 IgGs to transmembrane TNF-a. Transmembrane TNF-a-transfected NS0 cells were
incubated with serial log dilutions of m357 (#) or h357 (N
) antibody for 1 hr at 4uC. Cell were washed and incubated with Alexa Fluor 488 goat anti-
mouse IgG (H+L) for m357 and Alexa Fluor 647 goat anti-human IgG (H+L) for h357, respectively for 1 hr at 4uC. Cells were then washed and analyzed
by FACSCalibur flow cytometer.
doi:10.1371/journal.pone.0016373.g005
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retaining the antibody-antigen affinity. The next question is
whether this resurfacing approach is truly a way to generate non-
immunogenic proteins. Since antibody drugs are highly species
specific, it is difficult to assess the immune response in humans
when conducting preclinical animal experiments even with non-
human primates. The adopted three dimensional structure
resurfacing method currently we used is distinct from the in
silico primary structure-based algorisms which mainly focused on
MHC class II peptide binding predictions. Meanwhile, recently
developed T-cell based procedures are showing promise for
predicting potential immunogenicity with some biologics includ-
ing monoclonal antibodies. Further experimental work focusing
on both in silico and T-cell assays of the h357 IgG will be assessed
to further minimize the immunogenicity issues for drug
development.
Figure 6. ADCC and CDC of h357 and m357 IgGs against transmembrane TNF-a-expressing cells. Transmembrane TNF-a-expressing NS0
cells were incubated in the presence of different concentrations of h357 or m357 antibody for 1 hr. Subsequently, PBMCs for ADCC or human
complement-rich serum for CDC were used as effector cells and the source of complement, respectively, and transmembrane TNF-a-expressing cells
were used as targets. The cytotoxicity was calculated by measuring the amount of LDH released from the cytosol into the supernatant. Results are
presented as percent cell lysis in antibody treated groups compared to 100% lysis in lysis buffer treated cell group.
doi:10.1371/journal.pone.0016373.g006
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Ethics Statement
Human whole blood was collected from healthy donors at
Hsinchui Blood Center, Taiwan, under a protocol approved by
the Institutional Review Board of Industrial Technology Research
Institute (IRB number 9901008) and reviewed by the Joint
Institutional Review Board (http://www.jirb.org.tw/), case num-
ber 10-S-004, a committee for allowing all blood centers in
Taiwan to provided blood for research purposes from those donors
with written consent. All animal work was reviewed and approved
by the Institutional Animal Care and Use Committee of Industrial
Technology Research Institute (approval number ITRI-IACUC-
2010-030R).
Computer modeling of m357 for resurfacing
The homology modeling process of m357 was performed using
Discovery Studio Modeling 2.1 (Accelrys, Inc., San Diego, CA).
Two separate BLASTP searches were performed for VL and VH of
m357. For identifying the homology of m357 protein sequences,
sequences were analyzed by searching over the Protein Data Bank
(PDB) (http://www.rcsb.org/pdb/home/home.do). The three-
dimensional (3D) structure of the m357 Fv fragment was
constructed by homology modeling based on the structures of
the VH domain of the murine anti-breast tumor antibody Fab
fragment SM-3[PDB entry: 1SM3] [17] and the VL domain
structure of an anti-thermus aquaticus DNA polymerase I
monoclonal antibody Fab fragment [PDB entry: 1AY1] [18].
The final 3D model was generated by MODELLER module [28],
which implements an automated approach to comparative protein
structure modeling by satisfaction of spatial restraints. It
performed automatically protein homology modeling and loop
modeling for m357. Model building of the CDR loops were
performed by selecting template structures from the PDB database
with the highest sequence identity using Model antibody Loops
module and were refined using Loop Refinement module in order
to minimize steric clashes and ensure correct bond lengths and
angles. Then, this whole model could be further refined by
CHARMm [29] with Accelrys CHARMm forcefield in Discovery
Studio Modeling 2.1. The structure was energy-minimized in two
steps, first by 5000 steps of restrained steepest descent minimiza-
tion, and followed by another 5000 steps of conjugated gradient
minimization while the alpha carbons of the framework were held
fixed in position. The solvent-accessible surface areas of m357
residues were calculated on the three-dimensional model by the
AREAIMOL program [30]. The residues which relative accessi-
bility was greater than 30% were defined as being accessible.
Construction, expression and purification of humanized
anti-human TNF-a IgG
The total RNA of around 10
7 cells of the hybridoma 357-101-4
(ECACC No. 92030603) which secrete anti-human TNF-a IgG
(m357) was isolated and the first-strand cDNA was generated
using oligo (dT) primers with Superscript III reverse transcriptase
(Invitrogen, San Diego, CA). The cDNA fragments encoding the
heavy chain and light chain variable regions of m357 were
obtained by PCR with the Heavy Primers (Cat. No. 27-1586-01,
GE Healthcare) and the Light Primer Mix (Cat. No. 27-1583-01,
GE Healthcare), respectively. The cDNA fragments encoding the
humanized heavy chain and light chain variable regions of m357
were obtained by over-lapping PCR with primers covering the
humanized regions. For the construction of the heavy chain of the
humanized 357 (h357) antibody, the cDNA construct consisting
the murine Ig kappa-chain V-J2-C signal peptide derived from the
mammalian expression vector pSecTag2/Hygro (Invitrogen, San
Diego, CA), the VH region of h357, and the human IgG1 constant
region (CH1, hinge, CH2 and CH3) which derived from the
cloning vector pFUSE-CHIg-hG1 (Invivogen, San Diego, CA)
were obtained by over-lapping PCR, followed by sub-cloning into
the vector pSecTag2/Hygro (Invitrogen, San Diego, CA) at Nhe I
and Not I sites. For the construction of the light chain of the
humanized 357 (h357), the cDNA construct consisting the above
murine Ig kappa-chain V-J2-C signal peptide, the VL region of
h357, and the human kappa light chain constant region which
derived from the cloning vector pFUSE2-CLIg-hk (Invivogen, San
Diego, CA) were obtained by over-lapping PCR, followed by sub-
cloning into the mammalian expression vectors pcDNA3.3-TOPO
TA (Invitrogen, San Diego, CA). Plasmids containing the heavy
and light chain cDNAs of h357 IgG1 were co-transfected into
mouse myeloma NS0 cells (European Collection of Animal Cell
cultures, Salisbury, Wiltshire, UK) using Effectene (Qiagen). After
selection with hygromycin B (400 mg/ml) and G418 (800 mg/ml)
for 4 weeks, culture media from several stable clones were
screened by ELISA with human TNF-a as coating and anti-
human IgG Fcc-HRP as detection reagents. An h357 IgG1 high-
expressing clone was picked and cultured in shaker flask at an
initial seeding density of 5610
5 cells/ml in a chemically-defined
medium HyQNS0 (Hyclone) without serum addition. Media were
harvested 5 days later and h357 IgG1 was purified from the
supernatant by Protein A (GE Healthcare) chromatography.
Anti-TNF-a neutralization potency assay
Neutralizing activities of m357 and h357 against human TNF-a
were measured on the murine fibroblast L929 cells (ATCC Cat.
No. CCL-1) treated with actinomycin D according to the method
described previously[31]. Briefly, L929 cells were seeded in
triplicate at 3610
5 cells/well into a 96-well plate and cultured in
RPMI 1640 medium supplemented with 10% (v/v) fetal bovine
Figure 7. Assessment of scores in collagen antibody-induced
arthritic mice treated with h357 IgG and phosphate buffered
saline. At the time of disease onset (day 0), mice were given by intra-
peritoneal injection of h357 IgG (50 mg) or 100 ml of phosphate
buffered saline (non-treatment) once-daily for 9 consecutive days. The
arthritis scores were compared between non-treated (n=4) and h357
IgG (n=5) treated groups during the course of treatment. Scoring
results were expressed as mean 6 standard deviation (SD). When mice
were treated with h357 IgG, the rate of arthritis development was
significantly reduced (P,0.05).
doi:10.1371/journal.pone.0016373.g007
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prepared in medium containing actinomycin D (2 mg/ml) and
TNF-a (100 ng/ml) and incubated at 37uC for 16 hours. After the
supernatant were removed, 3-4,5-dimethylthiazol-2-yl-2,5-diphe-
nyltetrazolium bromide (MTT) (5 mg/ml) (Sigma-Aldrich) was
added and incubated in 37uC for 4 hours. SDS solution (10%) was
then added to the well. After 24 hours of incubation at room
temperature, color in each well was recorded by colorimeter at
570 nm. Blank control (culture alone), TNF-a control (TNF-a
alone), and antibody control (antibody alone) were also designed in
the experiment. The ED50 value was calculated by complex
sigmoid non-linear regression analysis using SigmaPlot software
(Systat software, Inc. Richmond, CA).
Stable expression of transmembrane TNF-a on NS0 cells
A mutant form of transmembrane TNF-a, which is resistant to
TNF-a converting enzyme-mediated cleavage, was generated by
site-directed mutagenesis as described previously [32]. In this
uncleavable form of transmembrane TNF-a, the amino acids +1
through +12 of the native transmembrane TNF-a were deleted.
An uncleavable form of transmembrane TNF-a gene was cloned
into pSecTag2/Hygro mammalian expression vector (Invitrogen,
San Diego, CA) and transfected into mouse myeloma NS0 cells by
Effectene for expressing transmembrane TNF-a on cell surface.
Antibody binding studies
The binding activities of h357 IgG, m357 IgG, etanercept and
adalimumab to soluble TNF-a were determined by ELISA. For
capturing h357 IgG, etanercept (Wyeth) and adalimumab
(Abbott), the microtiter plate was coated with 2 mg/ml of goat
anti-hunam IgG Fcc fragment (Jackson ImmunoResearch Labo-
ratories, Inc., West Grove, PA) in PBS overnight at 4uC. For
capturing m357 IgG, the microtiter plate was coated with goat
anti-mouse IgG Fcc fragment (Jackson ImmunoResearch Labo-
ratories, Inc., West Grove, PA). After blocking the wells with
StartingBlock
TM blocking buffer (Thermo Scientific), 2 mg/ml
each of the TNF-a antagonists, as mentioned above, were added
and incubated for 1 hr at 37uC. After washing, varing concentra-
tions of human recombinant TNF-a (eBioscience, Inc., San Diego,
CA) in PBS were incubated for 1 hr at 37uC. After washing, the
bound soluble TNF-a was detected by incubation with horseradish
peroxidase-conjuagted mouse monoclonal anti-TNF-a antibody
(clone F6C5, Abcam, Cambridge, MA) for 1 hr at 37uC and using
3,39,5,59,-tetramethylbenzidine as substrate. Absorbance was read
at 450 nm on a microplate reader. The dissociation constant (KD)
of each antagonist was calculated as the concentration of TNF-a
required to achieve half-saturation of the total binding sites
(maximum absorbance).
Saturation binding assay of m357 and h357 IgGs to
transmembrane TNF-a
NS0 cells stably expressing the transmembrane TNF-a were
incubated with serial log dilutions of m357 and h357 IgGs for
1h ra t4 uC in phosphate buffered saline (PBS) containing 2%
fetal bovine serum (fluorescence-activated cell sorting [FACS]
buffer). Cells were washed with a FACS buffer for 3 times and
were then stained with Alexa Fluor 488 conjugated goat anti-
mouse IgG (H+L) (Invitrogen, San Diego, CA) for m357 IgG
and Alexa Fluor 647 conjugated goat anti-human IgG (H+L)
(Invitrogen, San Diego, CA) for h357 IgG, respectively for 1 hr
at 4uC. Fluorescence intensities were measured using a
FACSCalibur flow cytometer (Becton Dickinson, San Jose,
CA).
ADCC and CDC assays
Peripheral blood mononuclear cells (PBMCs) were prepared by
Ficoll-Hypaque density gradient centrifugation. ADCC and CDC
activities of h357 and m357 IgGs were measured by LDH
Cytotoxicity Detection Kit (Clontech), which measures lactate
dehydrogenase (LDH) activity released from the cytosol of
damaged cells. Briefly, NS0 cells stably expressing the transmem-
brane TNF-a were incubated with different concentration of h357
or m357 IgG for 1 hr in assay medium (DMEM +1% FBS) in a
5% CO2 incubator at 37uC, followed by the addition of either
human peripheral blood mononuclear cells (PBMC) as effector
cells (effector to target ratio =20:1 for ADCC assay) or human
complement-rich serum (Quidel) (1.25% vol/vol, for CDC assay).
After an additional incubation for 16 hrs for ADCC assay and
5 hrs for CDC assay at 37uC, respectively, 100 ml of supernatant
from each well were transferred into a clean flat-bottom 96-well
plate. LDH substrate (100 ml) was added to each well and
incubated for 30 min at room temperature protected from light.
The absorbance of the samples was measure at 490 nm with an
ELISA reader. Maximum LDH release was determined by
incubating cells with lysis buffer. Percentage of specific lysis was
calculated according to the following formula: % cytotoxicity
=[experimental release – spontaneous release]/[maximum release
– spontaneous release]6100.
In vivo inhibition of murine collagen antibody-induced
arthritis with h357 IgG
For collagen antibody-induced arthritis experiments, 8- to10-
week old male DBA/1J mice were purchased from Jackson
laboratories (Bar Harbor, ME). Mice were maintained under a
climate controlled environment in a 12-h light/dark cycle.
Arthritic mice were induced by intra-peritoneal (i.p.) injection
of 3 mg/mouse of type II collagen specific antibodies (ModiQuest
Research). Mice were further boosted with 25 mg lipopolysac-
charides (LPS) (Sigma) by i.p. injection on day 6. Clinical arthritis
scores were evaluated using a scale of 0–2 for each paw for a total
score of 8. Paws were assigned a clinical score based on the index
(ModiQuest Research scoring method): 0= normal; 0.25= one
or two swollen toes; 0.5= three and four swollen toes; 0.75=
slightly swollen footpad or ankle; 1= swollen footpad or ankle;
1.25= one or two swollen toes and swollen footpad or ankle;
2.0= swollen toes and swollen footpad and swollen ankle. At the
time of disease onset, mice were administered by i.p. injection of
50 mg per does for 9 consecutive days. Scoring results were
expressed as mean 6 standard deviation (SD). Statistical
differences between the control (phosphate buffered saline) and
experimental groups were analyzed by Mann-Whitney U test for
the severity of arthritis.
Supporting Information
Figure S1 RT-PCR results showing the variable frag-
ments and schematic representation of the strategy to
assemble the heavy and light chains. (A) Amplification of
the variable fragment cDNAs from the mouse hybridoma 357-
101-4 secreting m357 IgG by RT-PCR with the Heavy Primers
(Cat. No. 27-1586-01, GE Healthcare) and the Light Primer Mix
(Cat. No. 27-1583-01, GE Healthcare), respectively. Lane M:
Molecular weight marker. Lane 1: VH, ,340 bp. Lane 2: VL,
,325 bp. (B) Assembly of the cDNAs encoding the open reading
frames of the heavy and light chains of the humanized 357 (h357)
IgG1 by over-lapping PCR, respectively. The cDNA construct
consisting the murine signal peptide (SP) derived from the cloning
vector pSecTag2/Hygro, the VH region of h357, and the human
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PLoS ONE | www.plosone.org 8 January 2011 | Volume 6 | Issue 1 | e16373IgG1 constant region (CH1, hinge, CH2 and CH3) derived from
the cloning vector pFUSE-CHIg-hG1 were obtained by over-
lapping PCR, followed by sub-cloning into the vector pSecTag2/
Hygro at Nhe I and Not I sites. The cDNA construct consisting
the above signal peptide, the VL region of h357, and the human
kappa light chain constant region derived from the cloning vector
pFUSE2-CLIg-hk were obtained by over-lapping PCR, followed
by sub-cloning into the mammalian expression vectors pcDNA3.3-
TOPO TA (Invitrogen, San Diego, CA). The locations of the
primers and the restriction sites are shown in the diagram. SP,
murine Ig kappa-chain V-J2-C signal peptide.
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